ABT•benzinga•
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Summary
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga